Keyphrases
Duchenne muscular Dystrophy
100%
Antisense
100%
Duchenne
100%
Small Animal Model
100%
Dystrophin
60%
Antisense Oligonucleotides
60%
Mdx Mice
40%
Moving Forward
20%
Functional Analysis
20%
Exon
20%
Therapeutic Approaches
20%
Myofiber
20%
Point mutation
20%
Adipogenic
20%
Exon Skipping
20%
Exon 53
20%
Rare Genetic Disease
20%
Exondys 51
20%
Promising Treatment
20%
Aged Mice
20%
Accelerated Approval
20%
Tail Vein
20%
Intravenous Delivery
20%
Molecular Assay
20%
Biochemistry, Genetics and Molecular Biology
Antisense
100%
Animal Model
100%
Oligonucleotide
75%
Dystrophin
75%
Exon
50%
Mouse Model
25%
Point Mutation
25%
In Vivo Study
25%
Genetic Disorder
25%
Exon Skipping
25%
Medicine and Dentistry
Duchenne Muscular Dystrophy
100%
Antisense
100%
Dystrophin
60%
Antisense Oligonucleotide
60%
Exon
40%
Deterioration
20%
Genetic Disorder
20%
Exon Skipping
20%
Neonatal Infant
20%
Oligonucleotide Targeting
20%
Tail Vein
20%
Point Mutation
20%
Immunology and Microbiology
Antisense
100%
Dystrophin
75%
Exon
50%
Mouse Model
25%
Exon Skipping
25%
Point Mutation
25%
Vein
25%
Pharmacology, Toxicology and Pharmaceutical Science
Duchenne Muscular Dystrophy
100%
Antisense Oligonucleotide
60%
Dystrophin
60%
Genetic Disorder
20%
Mouse Model
20%
Deterioration
20%
Oligonucleotide Targeting
20%